Midomafetamine
- Generic Name
- Midomafetamine
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
MDMA Plus Exposure Therapy for PTSD
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Emory University
- Target Recruit Count
- 40
- Registration Number
- NCT05746572
- Locations
- 🇺🇸
Emory Brain Health Center, Atlanta, Georgia, United States
Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.
- Conditions
- Post Traumatic Stress DisorderMDMA ('Ecstasy')Moral Injury
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 60
- Registration Number
- NCT05732155
MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder
- Conditions
- Post-traumatic Stress DisorderPTSDAlcohol Use DisorderAlcohol DependenceComorbidities and Coexisting Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 120
- Registration Number
- NCT05709353
- Locations
- 🇦🇺
Turning Point, Richmond, Victoria, Australia
🇦🇺Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Sunstone Medical
- Target Recruit Count
- 20
- Registration Number
- NCT05584826
- Locations
- 🇺🇸
Sunstone Medical, PC, Rockville, Maryland, United States
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 24
- Registration Number
- NCT05523401
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
Abuse Potential and Human Pharmacology of Methylone
- Conditions
- Substance UseHealthy Subjects
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT05488171
- Locations
- 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers
- Conditions
- Post-Traumatic Stress DisorderAdjustment Disorders
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Willa Hall
- Target Recruit Count
- 30
- Registration Number
- NCT05455996
Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
- Conditions
- Social BehaviorMotivationStimulant UseMDMA ('Ecstasy')
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 43
- Registration Number
- NCT05379959
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Acute Effects of R- and S-MDMA in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: R-3,4-methylenedioxymethamphetamine (250 mg)Drug: S-3,4-methylenedioxymethamphetamineDrug: R-3,4-methylenedioxymethamphetamine (125 mg)Other: Placebo
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 24
- Registration Number
- NCT05277636
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
MDMA for Co-occurring PTSD and OUD After Childbirth
- Conditions
- Stress Disorders, Post-TraumaticOpioid Use Disorder
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 15
- Registration Number
- NCT05219175
- Locations
- 🇺🇸
University of New Mexico Health Sciences, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.